Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-09-2006 | Original Paper

Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma

Authors: Rong-Ping Guo, Chong Zhong, Ming Shi, Chang-Qing Zhang, Wei Wei, Ya-Qi Zhang, Jin-Qing Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2006

Abstract

Purpose

Whereas some studies have indicated that the prognosis of hepatocellular carcinoma (HCC) was correlated to some apoptosis and angiogenesis factors: p53, survivin, matrix metalloproteinases (MMPs, including MMP-2 and MMP-9) and vascular endothelial growth factor (VEGF), other studies have failed to confirm this. The aim of the present study is to investigate the expression of p53, survivin, MMPs and VEGF in HCC and the relationship between these factors and the prognosis of HCC patients.

Methods

The expression of p53, survivin, MMP-2, MMP-9 and VEGF was measured by immunohistochemical assays in the liver resection specimens of 90 patients with HCC.

Results

The positive rate of p53, survivin, MMP-2, MMP-9 and VEGF was 33.3, 51.1, 60.0, 37.8 and 76.7%, respectively. The expression of MMP-2, MMP-9 and VEGF was correlated to the recurrence of HCC patients, respectively (P < 0.01). No correlation was found between the expression of apoptosis factors (p53 and survivin) and the recurrence of HCC patients, respectively (P > 0.05). The positive correlations were found between MMP-2 and VEGF (r = 0.32, P < 0.01), MMP-9 and VEGF (r = 0.24, P < 0.05). Significant differences of disease-free survival rates occurred among subgroups according to the expression of MMP-2, MMP-9 and VEGF (P < 0.01). Multivariate analysis revealed that macroscopically disseminated nodules, tumor micrometastasis, high serum alpha-fetoprotein level, positive expression of MMP-9 and VEGF were independent recurrence risk factors.

Conclusions

Our investigation revealed that p53 and survivin could not estimate the prognosis of HCC patients. Angiogenesis factors (MMPs and VEGF) positively correlated to the prognosis of HCC patients. The expression of MMPs and VEGF in HCC tissues could be regarded as a valuable indicator in estimating the prognosis of HCC patients.

Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology 32:1224–1229PubMedCrossRef

Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744PubMedCrossRef

Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with respectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355–362PubMedCrossRef

Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48900 necropsies. Cancer 7:462–503PubMedCrossRef

Farges O, Regimbeau JM, Belghiti J (1998) Aggressive management of recurrence following surgical resection of hepatocellular carcinoma. Hepatogastroenterology 45(s):1275–1280PubMed

Garzetti GG, Ciavattini A, Lucarini G, Pugnaloni A, De Nictolis M, Amati S, Romanini C, Biagini G (1999) Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 85:2219–2225PubMedCrossRef

Gorog D, Regoly Merei J, Paku S, Kopper L, Nagy P (2005) Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J Gastroenterol 11:5015–5018PubMed

Hayashi H, Sugio K, Matsumata T, Adachi E, Takenaka K, Sugimachi K (1995) The clinical significance of p53 gene mutation in hepatocellular carcinoma from Japan. Hepatology 22:1702–1707PubMed

Hermanek P, Hutter RV, Sobin LH, Wittekind C (1999) Classification of isolated tumor cells and micrometastasis. Cancer 86:2668–2673PubMedCrossRef

Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY (1993) Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 53:4691–4694PubMed

Ikeguchi M, Hirooka Y, Kaibara N (2002a) Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 95:1938–1945CrossRef

Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N (2002b) Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 11:33–40CrossRef

Ishii Y, Nakasato Y, Kobayashi S, Yamazaki Y, Aoki T (2003) A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 22:461–470PubMed

Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080–1085PubMedCrossRef

Jeng KS, Sheen IS, Chen BF, Wu JY (2000) Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg 135:1329–1333PubMedCrossRef

Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113–3119PubMed

Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M (2005) Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 35:53–60PubMedCrossRef

Kawakita N, Seki S, Sakaguchi H, Yanai A, Kuroki T, Mizoguchi Y, Kobayashi K, Monna T (1992) Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde. Am J Pathol 140:513–520PubMed

Maatta M, Soini Y, Liakka A, Autio-Harmainen H (2000) Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6:2726–2734PubMed

Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N (1998) Assessment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathological factors and prognosis. Clin Cancer Res 4:1475–1482PubMed

Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS (2003) Overexpression of VEGF and angioproietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 16:552–557PubMedCrossRef

Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y, Takemiya S (2004) Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 12:1189–1194PubMed

Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S (2005) Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103:307–312PubMedCrossRef

Nakano S, Haratake J, Okamoto K, Takeda S (1994) Investigation of resected multinodular hepatocellular carcinoma: assessment of unicentric or multicentric genesis from histological and prognosis viewpoint. Am J Gastroenterol 89:189–193PubMed

Nanashima A, Yano H, Yamaguchi H, Tanaka K, Shibasaki S, Sumida Y, Sawai T, Shindou H, Nakagoe T (2004) Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol 39:148–154PubMedCrossRef

Ng IO, Lai EC, Chan AS, So MK (1995) Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 10:250–255PubMedCrossRef

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (1999) Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229:216–222PubMedCrossRef

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646–649PubMedCrossRef

Qin LX, Tang ZY (2004) Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 130:497–513PubMedCrossRef

Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A (1999) Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br J Cancer 79:604–610PubMedCrossRef

Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ (2004) Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 28:376–381PubMedCrossRef

Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K (1993) Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res 53:2884–2887PubMed

The Liver Cancer Study Group of Japan (1990) Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 211:277–287

Unemori EN, Ferrara N, Bauer EA, Amento EP (1992) Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 153:557–562PubMedCrossRef

Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68–77PubMedCrossRef

Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, Fujimoto J, Oriyama T, Furukawa K, Kawamura E (1990) Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 65:1104–1110PubMedCrossRef

Title: Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma
Authors: Rong-Ping Guo
Chong Zhong
Ming Shi
Chang-Qing Zhang
Wei Wei
Ya-Qi Zhang
Jin-Qing Li
Publication date: 01-09-2006
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 9/2006
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0097-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2006

A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles

A soluble truncated cadherin induces breast cancer cell apoptosis and growth inhibition

A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma

Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity

Smoking cessation in long-term survivors of germ cell tumour

Breast conservative therapy in east part of China: a retrospective cohort study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page